Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15568212 | 0.78 | APLNR (0.61) | APLNRMAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL15781025 | 0.78 | APLNR (0.37) | APLNRMAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL11285851 | 0.77 | — | — | |
| SCHEMBL25610634 | 0.76 | MAPK1 (0.37) | APLNRMAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL4730994 | 0.74 | POLB (0.53) | APLNRMAPK1TP53LMNARAB9A | |
| SCHEMBL16469485 | 0.73 | APLNR (0.33) | APLNRMAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL26123902 | 0.71 | FFAR3 (0.46) | APLNRMAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL16469141 | 0.71 | NLRP3 (0.48) | APLNR | |
| SCHEMBL20169406 | 0.71 | APLNR (0.32) | APLNR | |
| SCHEMBL17893440 | 0.71 | CYP2C19 (0.55) | APLNRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3523293-B1 | SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS | ABBVIE OVERSEAS SARL (LU) | 2021-06-16 | — | — | EP | disclosed |
| US-10653673-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-10653673-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| EP-3523293-A1 | SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS | Abbvie S.a.r.l. (LU) | 2019-08-14 | — | — | EP | disclosed |
| US-20180161312-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | US | disclosed |
| US-20180161312-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | US | disclosed |
| US-20180161312-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | US | disclosed |
| US-9981910-B2 | Substituted pyrrolidines and methods of use | ABBVIE S.Á.R.L. (LU) | 2018-05-29 | — | — | US | disclosed |
| US-9974775-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-22 | — | — | US | disclosed |
| US-9974775-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-22 | — | — | US | disclosed |
| US-20160310468-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-27 | — | — | US | disclosed |
| US-20160310468-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-27 | — | — | US | disclosed |
| US-9453002-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| US-9453002-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| US-9453002-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| EP-3033337-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | Janssen Pharmaceutica, N.V. (BE) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015023289-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | WO | disclosed |
| US-20150051225-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051225-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051225-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051225-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1S | APLNR 2493/4885MAPK1 2955/4885TP53 4205/4885 |
| US-10653673-B2 | Substituted imidazoles as N-type calcium channel blockers | CACNA1B, CACNA1E, CACNA1S | APLNR 2493/4885MAPK1 2955/4885TP53 4205/4885 |
| US-20180161312-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1S | APLNR 2493/4885MAPK1 2955/4885TP53 4205/4885 |
| US-20160310468-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1S | APLNR 2493/4885MAPK1 2955/4885TP53 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.